Bioprinting certainly will play a major role in the future of medicine. Implantation of 3D printed bones, soft tissue, and eventually entire organs look to be on the horizon. With several companies working on the technology, and the science behind 3D bioprinting making huge strides in recent years, the entire medical field may be in for major disruptions.
Swansea University-based life science technology company 3Dynamic Systems Ltd (3DS) has developed two new additive manufacturing systems, but with a difference. These machines are capable of depositing a range of biologically active and biologically compatible materials. The company is working to fabricate 3D transplantable bone and complex tissue constructs on demand. This exciting breakthrough in tissue engineering technology developed by the company could one day be used to treat severely injured patients. The research has successfully engineered a suitable bone composite and a 3D-Bioprinting technology to make high complexity tissue structures. These have been determined to be optimum materials for producing reliable extra cellular matrix-based tissues.
The first system is the 3Dynamic Alpha Series, which is a single extrusion bone tissue fabrication platform. This machine produces calcium phosphate-based bone for regenerating severe non-stabalised fractures. By accurately depositing a special bone composite in 3D, the correct anatomical geometry is produced. This material is seeded with platelet-derived growth factor which creates the right environment for tissue regeneration by recruiting stem cells that can produce bone and forming a supportive structure, including blood vessels.
The second system is the dual extrusion 3Dynamic Omega Series bioprinter which is used to make three dimensional soft tissue constructs. Currently this is capable of producing heterogeneous tissues which are used for pharmaceutical testing trials. This technique is also being explored as a method for bioprinting different tissues including; muscle, adipose and skin. With this technology, techniques are being developed which could be an effective means toward producing transplantable complex tissues on demand.
3DS’ easy to use technology could see a greater adoption of bioprinting research and further innovation in the short-term by enabling researches in the field to effectively produce experimental tissues and multiple tissue types on demand. As a result the bioprinting technology developed by 3DS could one day transform the field of reconstructive medicine which may lead to direct bio-engineering replacement human tissues on-demand for transplantation. For further information visit bioprintingsystems.com. Let’s hear your thoughts on 3D bioprinting, and these new techniques in the 3Dynamic Systems bioprinting forum thread on 3DPB.com.
You May Also Like
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 3
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal, of 3D Hubs by ProtoLabs, and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest...
3D Printing News Briefs, January 23, 2021: CADENAS, BCN3D, ExOne & AMGTA, 6K
We’ve got some business news for you in this weekend edition of 3D Printing News Briefs! CADENAS and BCN3D are both reporting good news from 2020, and ExOne has just...
CEO Meddah Hadjar to Leave SLM Solutions
SLM Solutions (AM3D.DE) has announced that its CEO, Meddah Hadjar, will not be extending his contract with the company at the end of January 2021. The company has stated the...
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 2
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest from investors in our markets. Is 2021 going...
View our broad assortment of in house and third party products.